<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010126</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02086</org_study_id>
    <secondary_id>NCI-2012-02086</secondary_id>
    <secondary_id>NCI-2011-02504</secondary_id>
    <secondary_id>MC0845</secondary_id>
    <secondary_id>CDR0000653790</secondary_id>
    <secondary_id>NCI-2012-01049</secondary_id>
    <secondary_id>8233</secondary_id>
    <secondary_id>8233</secondary_id>
    <secondary_id>N01CM00032</secondary_id>
    <secondary_id>N01CM00038</secondary_id>
    <secondary_id>N01CM00039</secondary_id>
    <secondary_id>N01CM00070</secondary_id>
    <secondary_id>N01CM00071</secondary_id>
    <secondary_id>N01CM00099</secondary_id>
    <secondary_id>N01CM00100</secondary_id>
    <secondary_id>N01CM62201</secondary_id>
    <secondary_id>N01CM62203</secondary_id>
    <secondary_id>N01CM62204</secondary_id>
    <secondary_id>N01CM62205</secondary_id>
    <secondary_id>N01CM62206</secondary_id>
    <secondary_id>N01CM62207</secondary_id>
    <secondary_id>N01CM62208</secondary_id>
    <secondary_id>N01CM62209</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>P50CA102701</secondary_id>
    <nct_id>NCT01010126</nct_id>
  </id_info>
  <brief_title>Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer</brief_title>
  <official_title>A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well temsirolimus and bevacizumab work in treating patients
      with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer. Temsirolimus may
      stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
      Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some
      block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
      them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of
      cancer by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may
      kill more tumor cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the response rate and progression-free survival at 6 months in patients with
      endometrial, ovarian, hepatocellular carcinoma, carcinoid or islet cell cancer.

      II. To determine the toxicity of the combination of temsirolimus and bevacizumab in patients
      with endometrial, ovarian, hepatocellular carcinoma, carcinoid or islet cell cancer.

      SECONDARY OBJECTIVES:

      I. To collect blood and tumor specimens from all patients entered on the trial for possible
      future analysis.

      OUTLINE:

      Patients receive temsirolimus intravenously (IV) on days 1, 8, 15, and 22, and bevacizumab IV
      over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease
      progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 8, 2009</start_date>
  <completion_date type="Actual">March 13, 2017</completion_date>
  <primary_completion_date type="Actual">March 13, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The 6-month progression free survival rate is the proportion of evaluable patients progression-free 6 months from registration. The 6-month progression-free rate is defined as the total number of efficacy evaluable patients on study without documentation of disease progression 6 months from registration divided by the total number of evaluable patients enrolled on study. Kaplan-Meier methodology will be used to estimate the final success proportion (i.e. progression free at 6 months with a 95% confidence interval).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Response Rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Tumor response rate defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to the RECIST criteria divided by the total number of efficacy evaluable patients enrolled on study. Patients were evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. In brief, a Complete Response (CR) means the complete disappearance of all target lesions and a reduction in each lymph node to &lt;1 cm. A Partial Response (PR) is defined as a 30% decrease in the sum of the longest diameter of the non-nodal target lesion from baseline. Each requires no new lesions present at evaluation. The proportion of participants with a response is provided here for each cohort. The proportion was calculated as the number of patients that had a best response of CR or PR divided by the number of patients evaluated for a response in each cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Time from date at which the patient's objective status is first noted to be either a complete response (CR) or partial response (PR) to the date progression is documented, assessed up to 3 years</time_frame>
    <description>Duration of response is defined for all evaluable patients who have achieved a response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented. Objective response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) as described in Primary Objective 2 in this report. Median duration of response and the confidence interval for the median duration will be computed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Every cycle of treatment, up to 3 years</time_frame>
    <description>Adverse events are defined as events that are classified as either possibly, probably, or definitely related to study treatment, graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0. The number of patients reporting grade 3 or higher adverse events at least possibly related to treatment are reported here. For a complete list of all reported adverse events, please see the adverse events section of this report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time from registration to death, assessed up to 3 years</time_frame>
    <description>Survival time will be defined as the time from registration to death. Time to event distributions will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>Time from registration to disease progression, assessed up to 3 years</time_frame>
    <description>Time to progression is defined as the time from registration to disease progression. Patients who died without documentation of progression will be considered to have progressed on the date of their death. If a patient starts treatment and fails to return for evaluation, that patient will be censored for progression of disease at day one post-registration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Time from study entry to the date patients end treatment, assessed up to 3 years</time_frame>
    <description>Time to treatment failure is defined as the time from study entry to the date patients end treatment.Time to treatment failure will be evaluated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Adult Hepatocellular Carcinoma</condition>
  <condition>Advanced Adult Hepatocellular Carcinoma</condition>
  <condition>Endometrial Serous Adenocarcinoma</condition>
  <condition>Localized Non-Resectable Adult Liver Carcinoma</condition>
  <condition>Lung Carcinoid Tumor</condition>
  <condition>Malignant Pancreatic Gastrinoma</condition>
  <condition>Malignant Pancreatic Glucagonoma</condition>
  <condition>Malignant Pancreatic Insulinoma</condition>
  <condition>Malignant Pancreatic Somatostatinoma</condition>
  <condition>Metastatic Digestive System Neuroendocrine Tumor G1</condition>
  <condition>Ovarian Carcinosarcoma</condition>
  <condition>Ovarian Endometrioid Adenocarcinoma</condition>
  <condition>Ovarian Seromucinous Carcinoma</condition>
  <condition>Ovarian Serous Surface Papillary Adenocarcinoma</condition>
  <condition>Pancreatic Alpha Cell Adenoma</condition>
  <condition>Pancreatic Beta Cell Adenoma</condition>
  <condition>Pancreatic Delta Cell Adenoma</condition>
  <condition>Pancreatic G-Cell Adenoma</condition>
  <condition>Pancreatic Polypeptide Tumor</condition>
  <condition>Recurrent Adult Liver Carcinoma</condition>
  <condition>Recurrent Digestive System Neuroendocrine Tumor G1</condition>
  <condition>Recurrent Fallopian Tube Carcinoma</condition>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <condition>Recurrent Pancreatic Neuroendocrine Carcinoma</condition>
  <condition>Recurrent Primary Peritoneal Carcinoma</condition>
  <condition>Recurrent Uterine Corpus Carcinoma</condition>
  <condition>Regional Digestive System Neuroendocrine Tumor G1</condition>
  <condition>Stage IIIA Fallopian Tube Cancer</condition>
  <condition>Stage IIIA Ovarian Cancer</condition>
  <condition>Stage IIIA Primary Peritoneal Cancer</condition>
  <condition>Stage IIIA Uterine Corpus Cancer</condition>
  <condition>Stage IIIB Fallopian Tube Cancer</condition>
  <condition>Stage IIIB Ovarian Cancer</condition>
  <condition>Stage IIIB Primary Peritoneal Cancer</condition>
  <condition>Stage IIIB Uterine Corpus Cancer</condition>
  <condition>Stage IIIC Fallopian Tube Cancer</condition>
  <condition>Stage IIIC Ovarian Cancer</condition>
  <condition>Stage IIIC Primary Peritoneal Cancer</condition>
  <condition>Stage IIIC Uterine Corpus Cancer</condition>
  <condition>Stage IV Fallopian Tube Cancer</condition>
  <condition>Stage IV Ovarian Cancer</condition>
  <condition>Stage IV Primary Peritoneal Cancer</condition>
  <condition>Stage IVA Uterine Corpus Cancer</condition>
  <condition>Stage IVB Uterine Corpus Cancer</condition>
  <condition>Uterine Carcinosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (temsirolimus, bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive temsirolimus IV on days 1, 8, 15, and 22, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (temsirolimus, bevacizumab)</arm_group_label>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab Biosimilar BEVZ92</other_name>
    <other_name>Bevacizumab Biosimilar BI 695502</other_name>
    <other_name>Bevacizumab Biosimilar CBT 124</other_name>
    <other_name>Bevacizumab Biosimilar FKB238</other_name>
    <other_name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (temsirolimus, bevacizumab)</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>CCI-779 Rapamycin Analog</other_name>
    <other_name>Cell Cycle Inhibitor 779</other_name>
    <other_name>Rapamycin Analog</other_name>
    <other_name>Rapamycin Analog CCI-779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed endometrial (endometrioid, uterine,
             papillary serous carcinoma, and carcinosarcoma), ovarian (primary peritoneal/fallopian
             tube, serous, endometrioid, mixed, and poorly differentiated epithelial ovarian
             cancers [for purposes of eligibility, carcinosarcoma is considered a poorly
             differentiated carcinoma]), hepatocellular carcinoma, carcinoid or islet cell
             (neuroendocrine: well- or moderately-differentiated neuroendocrine) cancer which are
             locally advanced, recurrent, or metastatic

          -  Patients must have measurable disease; patients having only lesions measuring &gt;= 1 cm
             to &lt; 2 cm must use spiral computed tomography (CT) imaging for both pre- and
             post-treatment tumor assessments; patients who have had prior palliative radiotherapy
             to metastatic lesion(s) must have at least one measurable lesion(s) that have not been
             previously irradiated

          -  Radiation therapy (adjuvant or palliative) must be completed &gt;= 4 weeks prior to
             registration, if applicable

          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3

          -  Platelets &gt;= 75,000/mm^3

          -  Hemoglobin &gt;= 9.0 g/dL

          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN); Note: direct bilirubin and
             international normalized ratio (INR) for hepatocellular carcinoma (HCC) patients
             allowed as per Child-Turcotte-Pugh scoring

          -  Alkaline phosphatase =&lt; 2.5 x ULN (=&lt; 5 x ULN if liver metastasis is present or
             patient is in HCC cohort)

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =&lt;
             2.5 x ULN (=&lt; 5 x ULN if liver metastasis is present or patient is in HCC cohort)

          -  Creatinine =&lt;1.5 x ULN

          -  Urinalysis &lt; 2+ protein; urine protein should be screened by dipstick or urine
             analysis; for proteinuria &gt;= 2+, 24-hour urine protein should be obtained and the
             level should be &lt; 2 g for patient enrollment

          -  Fasting serum cholesterol =&lt; 350 mg/dL (=&lt; 9.0 mmol/L)

          -  Triglycerides =&lt; 1.5 x ULN (mg/dL or mmol/L); patients with triglyceride levels &gt; 1.5
             x ULN can be started on lipid lowering agents and reevaluated within 1 week; if levels
             go to =&lt; 1.5 x ULN, they can be considered for the trial and continue the lipid
             lowering agents; NOTE: cholesterol and triglyceride measurement and management are not
             required for single-agent bevacizumab cohort with islet cell carcinoma

          -  International normalized ratio (INR) =&lt; 1.5 (unless the patient is on full dose
             warfarin)

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

          -  Capable of understanding the investigational nature, potential risks and benefits of
             the study and able to provide valid informed consent

          -  Negative serum pregnancy test done =&lt; 7 days prior to registration, for women of
             childbearing potential only; NOTE: patients and their partners should be practicing an
             effective form of contraception during the study and for at least 3 months following
             the last dose of this combined therapy

          -  Full-dose anticoagulants, if a patient is receiving full-dose anticoagulants (except
             carcinoid tumors), the following criteria should be met for enrollment: the subject
             must have an in-range INR (usually between 2 and 3) on a stable dose of warfarin or on
             stable dose of low molecular weight (LMW) heparin

          -  Prior systemic treatments for metastatic disease are permitted, including targeted
             therapies, biologic response modifiers, chemotherapy, hormonal therapy, or
             investigational therapy; exception: in the case of endometrial cancer no prior
             chemotherapy for metastatic or recurrent disease is allowed; prior planned adjuvant
             chemotherapy is allowed

          -  Patients who have had prior anthracycline must have a normal ejection fraction on left
             ventricular ejection fraction (LVEF) assessment by multigated acquisition scan (MUGA)
             or echocardiogram (Echo) =&lt; 4 weeks prior to registration

          -  Availability of tissue if applicable (from the primary tumor or metastases) for tumor
             studies for banking; Note: in the case of hepatocellular cancer if diagnosed by
             clinical and radiologic criteria only, availability of tissue not applicable

          -  Willingness to donate blood for biomarker studies related to the type of therapies
             used in this trial and the tumor types being treated

          -  ENDOMETRIAL CANCER (PERMANENTLY CLOSED TO ENROLLMENT)

          -  Any hormonal therapy directed at the malignant tumor is allowed; NOTE: therapy must be
             discontinued at least one week prior to registration

          -  Prior systemic therapy including biologic and immunologic agents as adjuvant
             treatment, must be discontinued at least 3 weeks prior to registration

          -  Recurrent or persistent endometrial adenocarcinoma, uterine papillary serous carcinoma
             and carcinosarcoma which is refractory to curative therapy or established treatments;
             NOTE: histologic or cytologic confirmation of original primary tumor is required

          -  HEPATOCELLULAR CANCER (PERMANENTLY CLOSED TO ENROLLMENT)

          -  HCC confirmed by biopsy OR diagnosed by clinical and radiologic criteria; all of the
             following criteria must be met or a biopsy is required:

               -  Known cirrhosis or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV)
                  infection

               -  Hypervascular liver masses &gt; 2 cm, and either serum alpha-fetoprotein (AFP) &gt; 400
                  ng/ml, or

               -  AFP &gt; three times normal and doubling in value in the antecedent 3 months

          -  Child-Pugh A (=&lt; 6 points) or better liver status

          -  Prior regional treatments for liver metastasis are permitted including:

               -  Selective internal radiation therapy such as brachytherapy, cyberknife,
                  radiolabeled microsphere embolization, etc.

               -  Hepatic artery chemoembolization

               -  Hepatic artery embolization

               -  Hepatic artery infusional chemotherapy

               -  Radiofrequency ablation NOTE: patients must be &gt;= 4 weeks from treatment and show
                  progressive disease in the liver after regional therapy or must have measurable
                  disease outside the liver

          -  Concomitant anti-viral therapy is allowed

          -  History of prior varices or evidence of varices on pre-study CT/magnetic resonance
             imaging (MRI) imaging are required to undergo endoscopy =&lt; 4 weeks prior to
             registration; those who had received specific therapy (banding and/or sclerotherapy)
             and had not bled within the prior 6 months are eligible

          -  Suitably recovered from prior localized therapy, in the opinion of the investigator

          -  ISLET CELL CANCER AND CARCINOID TUMOR (PERMANENTLY CLOSED TO ENROLLMENT)

          -  Patient has evidence of progressive disease as documented by Response Evaluation
             Criteria in Solid Tumors (RECIST) =&lt; 7 months prior to study entry

          -  Carcinoid tumor cohort: prior and concurrent long-acting somatostatin analogue therapy
             is required; patient has to be on a stable dose of a long-acting somatostatin analogue
             &gt;= 2 months prior to study entry with documentation of progressive disease on current
             dose

          -  Islet cell tumor cohort: prior and/or concurrent long-acting somatostatin analogue
             therapy is allowed, but not required; if patient is continued on a long-acting
             somatostatin analogue, a stable dose for &gt;= 2 months prior to study entry is required
             with documentation of progressive disease on current dose

          -  Prior therapies allowed include:

               -  =&lt; 2 prior chemotherapy regimens

               -  Prior interferon &gt;= 4 weeks prior to registration

               -  Radiolabeled octreotide therapy (patients with prior radiolabeled octreotide
                  therapy should have progressive disease after such therapy)

               -  Other investigational therapy NOTE: islet Cell Single Agent Bevacizumab Cohort:
                  Prior mammalian target of rapamycin (mTOR) inhibitor is allowed

          -  Prior regional treatments for liver metastasis are permitted including:

               -  Selective internal radiation therapy such as brachytherapy, cyberknife,
                  radiolabeled microsphere embolization, etc.

               -  Hepatic artery chemoembolization

               -  Hepatic artery embolization

               -  Hepatic artery infusional chemotherapy

               -  Radiofrequency ablation NOTE: patients must be &gt;= 12 weeks from treatment and
                  show progressive disease in the liver after regional therapy or must have
                  measurable disease outside the liver

        Exclusion Criteria:

          -  Prior therapy with vascular endothelial growth factor receptor (VEGFR) targeting
             agents or mammalian target of rapamycin (mTOR) inhibitors (except as in HCC and in the
             Islet cell single agent bevacizumab alone cohort where prior mTOR inhibitor is
             allowed); Note: prior use of bevacizumab is not allowed in any cohort

          -  Invasive procedures defined as follows:

               -  Major surgical procedure, open biopsy or significant traumatic injury =&lt; 4 weeks
                  prior to registration

               -  Anticipation of need for major surgical procedures during the course of the study

               -  Core biopsy =&lt; 7 days prior to registration

          -  Serious or non-healing wound, ulcer or bone fracture

          -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess
             =&lt; 180 days prior to first date of bevacizumab therapy

          -  Evidence of bleeding diathesis or coagulopathy in the absence of therapeutic
             anticoagulation

          -  Evidence of a history bleeding =&lt; 6 months such as hemoptysis, or cerebrovascular
             accident =&lt; previous 6 months, or peripheral vascular disease with claudication on &lt; 1
             block, or history of clinically significant bleeding, because of the potential
             bleeding and/or clotting risk with bevacizumab

          -  Untreated central nervous system (CNS) metastases; exceptions: patients with known CNS
             metastases can be enrolled if the brain metastases have been adequately treated and
             there is no evidence of progression or hemorrhage after treatment as ascertained by
             clinical examination and brain imaging (MRI or CT) =&lt; 12 weeks prior to registration
             and no ongoing requirement for steroids

               -  Anticonvulsants (stable dose) are allowed

               -  Patients who had surgical resection of CNS metastases or brain biopsy =&lt; 3 months
                  prior to registration will be excluded

          -  Significant cardiovascular disease defined as congestive heart failure (New York Heart
             Association class II, III or IV), angina pectoris requiring nitrate therapy, or recent
             myocardial infarction (=&lt; 6 months prior to registration)

          -  Uncontrolled hypertension (defined as a blood pressure of &gt;= 150 mmHg systolic and/or
             &gt;= 90 mmHg diastolic)

          -  Patient is on angiotensin-converting-enzyme (ACE) inhibitors (benazapril, captopril,
             enalopril, fosonopril, lisinopril, moexipril, perindopril, quinopril, ramipril, and
             trandolapril); (patients may have an alternate antihypertensive substituted); NOTE:
             ACE inhibitors are allowed in single agent bevacizumab cohort

          -  Currently active, second malignancy other than non-melanoma skin cancers; NOTE:
             patients are not considered to have a 'currently active' malignancy if they have
             completed anti-cancer therapy and are considered by their physician to be at less than
             30% risk of relapse

          -  Any of the following, as this regimen may be harmful to a developing fetus or nursing
             child:

               -  Pregnant women

               -  Breastfeeding women

               -  Men or women of childbearing potential or their sexual partners who are unwilling
                  to employ adequate contraception (diaphragm, birth control pills, injections,
                  intrauterine device [IUD], surgical sterilization, subcutaneous implants, or
                  abstinence, etc.) NOTE: the effects of the agent(s) on the developing human fetus
                  at the recommended therapeutic dose are unknown

          -  Known hypersensitivity to other recombinant human antibodies or Chinese hamster ovary
             cell products

          -  Other uncontrolled serious medical or psychiatric condition (e.g. cardiac arrhythmias,
             diabetes, etc.)

          -  Current therapy with a cytochrome P450 3A4 (CYP3A4) inhibitor or inducer; NOTE: these
             agents are allowed in the single-agent bevacizumab islet cell carcinoma cohort

          -  Active infection requiring antibiotics

          -  Active bleeding or pathological conditions that carry high risk of bleeding (e.g.
             tumor involving major vessels, known varices)

          -  Known human immunodeficiency virus (HIV)-positive

          -  ENDOMETRIAL CANCER (PERAMANENTLY CLOSED TO ENROLLMENT)

          -  Received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER
             THAN for the treatment of endometrial cancer

          -  Any chemotherapy for metastatic or recurrent cancer

          -  Radiation therapy to &gt; 25% of marrow bearing areas

          -  HEPATOCELLULAR CANCER EXCLUSION (PERMANENTLY CLOSED TO ENROLLMENT)

          -  Child-Pugh B or C classification

          -  Grade &gt;= 3 hemorrhage =&lt; 4 weeks prior to registration

          -  Prior liver transplant with evidence of recurrent or metastatic disease

          -  Patients on an active liver transplant list and considered likely to receive a liver
             transplant =&lt; 6 months following registration

          -  Clinical evidence of encephalopathy

          -  Prior treatment with sorafenib or other vascular endothelial growth factor (VEGF)
             inhibitors; NOTE: Exceptions allowed for patients unable to tolerate the agent;
             intolerance is defined in this protocol as a discontinued agent due to side effects
             with an exposure &lt; to 4 weeks of drug, at any dose level

          -  OVARIAN CANCER (PERMANENTLY CLOSED TO ENROLLMENT)

          -  Clinical signs and symptoms of gastrointestinal (GI) obstruction and require parental
             hydration/nutrition or tube feeding

          -  Evidence of free abdominal air not explained by paracentesis or recent surgical
             procedures

          -  Received more than two prior cytotoxic chemotherapy regimens for persistent or
             recurrent disease

          -  CARCINOID (PERMANENTLY CLOSED TO ENROLLMENT)

          -  Patients on anticoagulant therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Pitot</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tower Cancer Research Foundation</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211-1850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles County-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope South Pasadena</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center of Decatur</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crossroads Cancer Center</name>
      <address>
        <city>Effingham</city>
        <state>Illinois</state>
        <zip>62401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Saint Joseph Medical Center</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Ridges Hospital</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview-Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unity Hospital</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchinson Area Health Care</name>
      <address>
        <city>Hutchinson</city>
        <state>Minnesota</state>
        <zip>55350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology PA-Maplewood</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John's Hospital - Healtheast</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott-Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Memorial Medical Health Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Minnesota Community Oncology Research Consortium</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Clinic - Saint Louis Park</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Regional Medical Center</name>
      <address>
        <city>Shakopee</city>
        <state>Minnesota</state>
        <zip>55379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeview Hospital</name>
      <address>
        <city>Stillwater</city>
        <state>Minnesota</state>
        <zip>55082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ridgeview Medical Center</name>
      <address>
        <city>Waconia</city>
        <state>Minnesota</state>
        <zip>55387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rice Memorial Hospital</name>
      <address>
        <city>Willmar</city>
        <state>Minnesota</state>
        <zip>56201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology PA-Woodbury</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Sleepy Hollow</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health Partners - Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 6, 2009</study_first_submitted>
  <study_first_submitted_qc>November 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2009</study_first_posted>
  <results_first_submitted>September 20, 2018</results_first_submitted>
  <results_first_submitted_qc>January 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2019</results_first_posted>
  <last_update_submitted>January 24, 2019</last_update_submitted>
  <last_update_submitted_qc>January 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Carcinosarcoma</mesh_term>
    <mesh_term>Mixed Tumor, Mullerian</mesh_term>
    <mesh_term>Insulinoma</mesh_term>
    <mesh_term>Gastrinoma</mesh_term>
    <mesh_term>Glucagonoma</mesh_term>
    <mesh_term>Somatostatinoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Islet Cell</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma, Papillary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT01010126/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Endometrial Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Ovarian Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P3">
          <title>Hepatocellular Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P4">
          <title>Carcinoid Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P5">
          <title>Islet Cell (Double Agent) Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P6">
          <title>Islet Cell (Bevacizumab-only) Cohort</title>
          <description>Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="57"/>
                <participants group_id="P5" count="58"/>
                <participants group_id="P6" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="57"/>
                <participants group_id="P5" count="55"/>
                <participants group_id="P6" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Endometrial Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Ovarian Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Hepatocellular Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B4">
          <title>Carcinoid Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B5">
          <title>Islet Cell (Double Agent) Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B6">
          <title>Islet Cell (Bevacizumab-only) Cohort</title>
          <description>Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="57"/>
            <count group_id="B5" value="58"/>
            <count group_id="B6" value="24"/>
            <count group_id="B7" value="250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="40" upper_limit="80"/>
                    <measurement group_id="B2" value="62.5" lower_limit="35" upper_limit="82"/>
                    <measurement group_id="B3" value="59" lower_limit="31" upper_limit="74"/>
                    <measurement group_id="B4" value="62" lower_limit="35" upper_limit="89"/>
                    <measurement group_id="B5" value="58.5" lower_limit="29" upper_limit="81"/>
                    <measurement group_id="B6" value="54.5" lower_limit="40" upper_limit="78"/>
                    <measurement group_id="B7" value="60" lower_limit="29" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="159"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="57"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="212"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival Rate</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The 6-month progression free survival rate is the proportion of evaluable patients progression-free 6 months from registration. The 6-month progression-free rate is defined as the total number of efficacy evaluable patients on study without documentation of disease progression 6 months from registration divided by the total number of evaluable patients enrolled on study. Kaplan-Meier methodology will be used to estimate the final success proportion (i.e. progression free at 6 months with a 95% confidence interval).</description>
        <time_frame>6 months</time_frame>
        <population>All patients that received study treatment and were evaluated for response are included in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Endometrial Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Ovarian Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Hepatocellular Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Carcinoid Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Islet Cell (Double Agent) Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Islet Cell (Bevacizumab-only) Cohort</title>
            <description>Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Rate</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The 6-month progression free survival rate is the proportion of evaluable patients progression-free 6 months from registration. The 6-month progression-free rate is defined as the total number of efficacy evaluable patients on study without documentation of disease progression 6 months from registration divided by the total number of evaluable patients enrolled on study. Kaplan-Meier methodology will be used to estimate the final success proportion (i.e. progression free at 6 months with a 95% confidence interval).</description>
          <population>All patients that received study treatment and were evaluated for response are included in this analysis</population>
          <units>proportion of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.35" upper_limit="0.77"/>
                    <measurement group_id="O2" value="0.40" lower_limit="0.29" upper_limit="0.55"/>
                    <measurement group_id="O3" value="0.71" lower_limit="0.54" upper_limit="0.94"/>
                    <measurement group_id="O4" value="0.84" lower_limit="0.75" upper_limit="0.95"/>
                    <measurement group_id="O5" value="0.85" lower_limit="0.75" upper_limit="0.95"/>
                    <measurement group_id="O6" value="0.87" lower_limit="0.74" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response Rate</title>
        <description>Tumor response rate defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to the RECIST criteria divided by the total number of efficacy evaluable patients enrolled on study. Patients were evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. In brief, a Complete Response (CR) means the complete disappearance of all target lesions and a reduction in each lymph node to &lt;1 cm. A Partial Response (PR) is defined as a 30% decrease in the sum of the longest diameter of the non-nodal target lesion from baseline. Each requires no new lesions present at evaluation. The proportion of participants with a response is provided here for each cohort. The proportion was calculated as the number of patients that had a best response of CR or PR divided by the number of patients evaluated for a response in each cohort.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>For this analysis, the number of patients that had a best response of CR or PR were divided by the number of patients evaluated for a response.</population>
        <group_list>
          <group group_id="O1">
            <title>Endometrial Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Ovarian Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Hepatocellular Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Carcinoid Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Islet Cell (Double Agent) Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Islet Cell (Bevacizumab-only) Cohort</title>
            <description>Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response Rate</title>
          <description>Tumor response rate defined as the total number of efficacy-evaluable patients who achieved a complete or partial response according to the RECIST criteria divided by the total number of efficacy evaluable patients enrolled on study. Patients were evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. In brief, a Complete Response (CR) means the complete disappearance of all target lesions and a reduction in each lymph node to &lt;1 cm. A Partial Response (PR) is defined as a 30% decrease in the sum of the longest diameter of the non-nodal target lesion from baseline. Each requires no new lesions present at evaluation. The proportion of participants with a response is provided here for each cohort. The proportion was calculated as the number of patients that had a best response of CR or PR divided by the number of patients evaluated for a response in each cohort.</description>
          <population>For this analysis, the number of patients that had a best response of CR or PR were divided by the number of patients evaluated for a response.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" lower_limit="0.14" upper_limit="0.52"/>
                    <measurement group_id="O2" value="0.31" lower_limit="0.20" upper_limit="0.45"/>
                    <measurement group_id="O3" value="0.19" lower_limit="0.06" upper_limit="0.38"/>
                    <measurement group_id="O4" value="0.12" lower_limit="0.05" upper_limit="0.24"/>
                    <measurement group_id="O5" value="0.40" lower_limit="0.27" upper_limit="0.53"/>
                    <measurement group_id="O6" value="0.17" lower_limit="0.05" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Duration of response is defined for all evaluable patients who have achieved a response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented. Objective response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) as described in Primary Objective 2 in this report. Median duration of response and the confidence interval for the median duration will be computed.</description>
        <time_frame>Time from date at which the patient's objective status is first noted to be either a complete response (CR) or partial response (PR) to the date progression is documented, assessed up to 3 years</time_frame>
        <population>All patients that were assessed as a Complete Response or Partial Response were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Endometrial Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Ovarian Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Hepatocellular Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Carcinoid Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Islet Cell (Double Agent) Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Islet Cell (Bevacizumab-only) Cohort</title>
            <description>Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response is defined for all evaluable patients who have achieved a response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented. Objective response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) as described in Primary Objective 2 in this report. Median duration of response and the confidence interval for the median duration will be computed.</description>
          <population>All patients that were assessed as a Complete Response or Partial Response were included in this analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" lower_limit="0" upper_limit="35.5"/>
                    <measurement group_id="O2" value="6.4" lower_limit="3.7" upper_limit="10.8"/>
                    <measurement group_id="O3" value="6.4" lower_limit="0" upper_limit="11.1"/>
                    <measurement group_id="O4" value="15.0" lower_limit="0" upper_limit="18.8"/>
                    <measurement group_id="O5" value="11.3" lower_limit="8.8" upper_limit="21.2"/>
                    <measurement group_id="O6" value="10.9" lower_limit="3.7" upper_limit="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <description>Adverse events are defined as events that are classified as either possibly, probably, or definitely related to study treatment, graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0. The number of patients reporting grade 3 or higher adverse events at least possibly related to treatment are reported here. For a complete list of all reported adverse events, please see the adverse events section of this report.</description>
        <time_frame>Every cycle of treatment, up to 3 years</time_frame>
        <population>All patients that received protocol treatment and were evaluated for adverse events are reported in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Endometrial Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Ovarian Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Hepatocellular Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Carcinoid Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Islet Cell (Double Agent) Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Islet Cell (Bevacizumab-only) Cohort</title>
            <description>Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Adverse events are defined as events that are classified as either possibly, probably, or definitely related to study treatment, graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0. The number of patients reporting grade 3 or higher adverse events at least possibly related to treatment are reported here. For a complete list of all reported adverse events, please see the adverse events section of this report.</description>
          <population>All patients that received protocol treatment and were evaluated for adverse events are reported in this analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Survival time will be defined as the time from registration to death. Time to event distributions will be estimated using the Kaplan-Meier method.</description>
        <time_frame>Time from registration to death, assessed up to 3 years</time_frame>
        <population>All patients that received study intervention and were followed for survival were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Endometrial Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Ovarian Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Hepatocellular Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Carcinoid Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Islet Cell (Double Agent) Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Islet Cell (Bevacizumab-only) Cohort</title>
            <description>Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Survival time will be defined as the time from registration to death. Time to event distributions will be estimated using the Kaplan-Meier method.</description>
          <population>All patients that received study intervention and were followed for survival were included in this analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="57"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="6.5" upper_limit="NA">Too few deaths occurred to estimate an upper 95% CI.</measurement>
                    <measurement group_id="O2" value="16.3" lower_limit="11.1" upper_limit="21.9"/>
                    <measurement group_id="O3" value="14.8" lower_limit="9.7" upper_limit="18.1"/>
                    <measurement group_id="O4" value="32.7" lower_limit="25.2" upper_limit="38.3"/>
                    <measurement group_id="O5" value="35.0" lower_limit="14.6" upper_limit="NA">Too few deaths occurred to estimate an upper 95% CI.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="30.6" upper_limit="NA">Too few deaths occurred to estimate a median or an upper 95% CI.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression</title>
        <description>Time to progression is defined as the time from registration to disease progression. Patients who died without documentation of progression will be considered to have progressed on the date of their death. If a patient starts treatment and fails to return for evaluation, that patient will be censored for progression of disease at day one post-registration.</description>
        <time_frame>Time from registration to disease progression, assessed up to 3 years</time_frame>
        <population>All patients that began protocol treatment and were evaluated for response are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Endometrial Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Ovarian Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Hepatocellular Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Carcinoid Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Islet Cell (Double Agent) Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Islet Cell (Bevacizumab-only) Cohort</title>
            <description>Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression</title>
          <description>Time to progression is defined as the time from registration to disease progression. Patients who died without documentation of progression will be considered to have progressed on the date of their death. If a patient starts treatment and fails to return for evaluation, that patient will be censored for progression of disease at day one post-registration.</description>
          <population>All patients that began protocol treatment and were evaluated for response are included in this analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="2.5" upper_limit="9.8"/>
                    <measurement group_id="O2" value="5.6" lower_limit="4.3" upper_limit="6.4"/>
                    <measurement group_id="O3" value="8.0" lower_limit="5.8" upper_limit="10.9"/>
                    <measurement group_id="O4" value="15.2" lower_limit="11.4" upper_limit="24.2"/>
                    <measurement group_id="O5" value="13.1" lower_limit="11.2" upper_limit="16.6"/>
                    <measurement group_id="O6" value="18.0" lower_limit="10.6" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <description>Time to treatment failure is defined as the time from study entry to the date patients end treatment.Time to treatment failure will be evaluated using the method of Kaplan-Meier.</description>
        <time_frame>Time from study entry to the date patients end treatment, assessed up to 3 years</time_frame>
        <population>All patients that began study treatment were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Endometrial Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Ovarian Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Hepatocellular Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Carcinoid Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>Islet Cell (Double Agent) Cohort</title>
            <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O6">
            <title>Islet Cell (Bevacizumab-only) Cohort</title>
            <description>Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure</title>
          <description>Time to treatment failure is defined as the time from study entry to the date patients end treatment.Time to treatment failure will be evaluated using the method of Kaplan-Meier.</description>
          <population>All patients that began study treatment were included in this analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="2.3" upper_limit="6.4"/>
                    <measurement group_id="O2" value="4.5" lower_limit="2.7" upper_limit="5.6"/>
                    <measurement group_id="O3" value="6.5" lower_limit="2.3" upper_limit="8.0"/>
                    <measurement group_id="O4" value="5.5" lower_limit="4.4" upper_limit="8.1"/>
                    <measurement group_id="O5" value="11.3" lower_limit="8.6" upper_limit="13.3"/>
                    <measurement group_id="O6" value="11.8" lower_limit="5.8" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected at the end of each 28 day cycle for a maximum of 58 cycles.</time_frame>
      <desc>Adverse events were collected at the end of each 28 day cycle for a maximum of 58 cycles.</desc>
      <group_list>
        <group group_id="E1">
          <title>Endometrial Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Ovarian Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E3">
          <title>Hepatocellular Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E4">
          <title>Carcinoid Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E5">
          <title>Islet Cell (Double Agent) Cohort</title>
          <description>Patients receive 25 mg temsirolimus IV on days 1, 8, 15, and 22, and 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E6">
          <title>Islet Cell (Bevacizumab-only) Cohort</title>
          <description>Patients receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cardiac pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Duodenal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ear, nose and throat examination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Esophageal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Esophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rectal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Visceral edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gallbladder infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Postoperative hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rectal anastomotic leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum cholesterol increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum albumin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum potassium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Buttock pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Protein urine positive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urogenital disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vaginal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Visceral arterial ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="79" subjects_affected="20" subjects_at_risk="26"/>
                <counts group_id="E2" events="212" subjects_affected="48" subjects_at_risk="58"/>
                <counts group_id="E3" events="122" subjects_affected="23" subjects_at_risk="27"/>
                <counts group_id="E4" events="382" subjects_affected="49" subjects_at_risk="57"/>
                <counts group_id="E5" events="556" subjects_affected="49" subjects_at_risk="55"/>
                <counts group_id="E6" events="82" subjects_affected="8" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="9" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="10" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphatic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="13" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="7" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cardiac pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>External ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hearing test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Middle ear inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="7" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="45" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flashing vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="8" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" events="13" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="9" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="21" subjects_affected="13" subjects_at_risk="58"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="27" subjects_affected="11" subjects_at_risk="57"/>
                <counts group_id="E5" events="19" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anal mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="25" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E5" events="17" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="36" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" events="39" subjects_affected="18" subjects_at_risk="58"/>
                <counts group_id="E3" events="20" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E4" events="113" subjects_affected="33" subjects_at_risk="57"/>
                <counts group_id="E5" events="73" subjects_affected="21" subjects_at_risk="55"/>
                <counts group_id="E6" events="20" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="28" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="24" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="12" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="15" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ear, nose and throat examination abnormal</sub_title>
                <counts group_id="E1" events="31" subjects_affected="12" subjects_at_risk="26"/>
                <counts group_id="E2" events="44" subjects_affected="18" subjects_at_risk="58"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="76" subjects_affected="28" subjects_at_risk="57"/>
                <counts group_id="E5" events="116" subjects_affected="33" subjects_at_risk="55"/>
                <counts group_id="E6" events="23" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Esophageal mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastric mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E5" events="8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastroscopy abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="15" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="15" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E5" events="8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lip pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="6" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="9" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="86" subjects_affected="27" subjects_at_risk="58"/>
                <counts group_id="E3" events="27" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E4" events="25" subjects_affected="17" subjects_at_risk="57"/>
                <counts group_id="E5" events="43" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="63" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E2" events="49" subjects_affected="24" subjects_at_risk="58"/>
                <counts group_id="E3" events="22" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E4" events="63" subjects_affected="23" subjects_at_risk="57"/>
                <counts group_id="E5" events="69" subjects_affected="22" subjects_at_risk="55"/>
                <counts group_id="E6" events="13" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oesophagoscopy abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="10" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="17" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E5" events="13" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rectal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="10" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rectal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="8" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="12" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E5" events="21" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E4" events="24" subjects_affected="13" subjects_at_risk="57"/>
                <counts group_id="E5" events="26" subjects_affected="17" subjects_at_risk="55"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="12" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="22" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="25" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E3" events="8" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="55" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E5" events="70" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="120" subjects_affected="21" subjects_at_risk="26"/>
                <counts group_id="E2" events="152" subjects_affected="43" subjects_at_risk="58"/>
                <counts group_id="E3" events="67" subjects_affected="14" subjects_at_risk="27"/>
                <counts group_id="E4" events="236" subjects_affected="40" subjects_at_risk="57"/>
                <counts group_id="E5" events="293" subjects_affected="48" subjects_at_risk="55"/>
                <counts group_id="E6" events="70" subjects_affected="12" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gait abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="8" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="15" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="31" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="57" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Immune system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Joint infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lip infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="6" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="9" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="18" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Radiation recall reaction (dermatologic)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tracheal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="8" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="28" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" events="24" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E3" events="33" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" events="62" subjects_affected="18" subjects_at_risk="57"/>
                <counts group_id="E5" events="113" subjects_affected="25" subjects_at_risk="55"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="33" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" events="24" subjects_affected="13" subjects_at_risk="58"/>
                <counts group_id="E3" events="17" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="114" subjects_affected="20" subjects_at_risk="57"/>
                <counts group_id="E5" events="76" subjects_affected="19" subjects_at_risk="55"/>
                <counts group_id="E6" events="22" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="40" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E2" events="43" subjects_affected="20" subjects_at_risk="58"/>
                <counts group_id="E3" events="47" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E4" events="100" subjects_affected="24" subjects_at_risk="57"/>
                <counts group_id="E5" events="120" subjects_affected="31" subjects_at_risk="55"/>
                <counts group_id="E6" events="9" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="21" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E4" events="48" subjects_affected="14" subjects_at_risk="57"/>
                <counts group_id="E5" events="40" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="29" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E3" events="7" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="60" subjects_affected="18" subjects_at_risk="57"/>
                <counts group_id="E5" events="42" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E6" events="7" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fibrinogen decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="26" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E2" events="108" subjects_affected="30" subjects_at_risk="58"/>
                <counts group_id="E3" events="91" subjects_affected="16" subjects_at_risk="27"/>
                <counts group_id="E4" events="158" subjects_affected="38" subjects_at_risk="57"/>
                <counts group_id="E5" events="289" subjects_affected="34" subjects_at_risk="55"/>
                <counts group_id="E6" events="12" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E3" events="21" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" events="72" subjects_affected="16" subjects_at_risk="57"/>
                <counts group_id="E5" events="99" subjects_affected="19" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E2" events="55" subjects_affected="25" subjects_at_risk="58"/>
                <counts group_id="E3" events="54" subjects_affected="15" subjects_at_risk="27"/>
                <counts group_id="E4" events="62" subjects_affected="21" subjects_at_risk="57"/>
                <counts group_id="E5" events="130" subjects_affected="28" subjects_at_risk="55"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="53" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E2" events="86" subjects_affected="27" subjects_at_risk="58"/>
                <counts group_id="E3" events="159" subjects_affected="22" subjects_at_risk="27"/>
                <counts group_id="E4" events="327" subjects_affected="50" subjects_at_risk="57"/>
                <counts group_id="E5" events="479" subjects_affected="41" subjects_at_risk="55"/>
                <counts group_id="E6" events="52" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum cholesterol increased</sub_title>
                <counts group_id="E1" events="147" subjects_affected="22" subjects_at_risk="26"/>
                <counts group_id="E2" events="162" subjects_affected="38" subjects_at_risk="58"/>
                <counts group_id="E3" events="49" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E4" events="231" subjects_affected="38" subjects_at_risk="57"/>
                <counts group_id="E5" events="408" subjects_affected="46" subjects_at_risk="55"/>
                <counts group_id="E6" events="10" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" events="29" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E3" events="30" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" events="73" subjects_affected="20" subjects_at_risk="57"/>
                <counts group_id="E5" events="38" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E2" events="59" subjects_affected="23" subjects_at_risk="58"/>
                <counts group_id="E3" events="28" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E4" events="72" subjects_affected="27" subjects_at_risk="57"/>
                <counts group_id="E5" events="70" subjects_affected="29" subjects_at_risk="55"/>
                <counts group_id="E6" events="14" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="43" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E2" events="24" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="159" subjects_affected="30" subjects_at_risk="57"/>
                <counts group_id="E5" events="138" subjects_affected="28" subjects_at_risk="55"/>
                <counts group_id="E6" events="33" subjects_affected="11" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum albumin decreased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E3" events="11" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="37" subjects_affected="13" subjects_at_risk="57"/>
                <counts group_id="E5" events="49" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum calcium decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="23" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E5" events="61" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum calcium increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="10" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum magnesium decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="9" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="25" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E5" events="22" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum potassium decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="63" subjects_affected="25" subjects_at_risk="57"/>
                <counts group_id="E5" events="25" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="15" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E5" events="42" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum sodium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Serum triglycerides increased</sub_title>
                <counts group_id="E1" events="115" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E2" events="73" subjects_affected="25" subjects_at_risk="58"/>
                <counts group_id="E3" events="18" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E4" events="176" subjects_affected="29" subjects_at_risk="57"/>
                <counts group_id="E5" events="172" subjects_affected="32" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Buttock pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Joint disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="41" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="7" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="11" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="11" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E5" events="16" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="5" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="41" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="18" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="10" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="13" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E6" events="11" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Glossopharyngeal nerve disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="39" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" events="53" subjects_affected="23" subjects_at_risk="58"/>
                <counts group_id="E3" events="11" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E4" events="76" subjects_affected="20" subjects_at_risk="57"/>
                <counts group_id="E5" events="117" subjects_affected="25" subjects_at_risk="55"/>
                <counts group_id="E6" events="21" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Mini mental status examination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="12" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="14" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E5" events="26" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Recurrent laryngeal nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" events="39" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" events="67" subjects_affected="12" subjects_at_risk="58"/>
                <counts group_id="E3" events="22" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E4" events="41" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E5" events="70" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="6" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="10" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="10" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" events="25" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="31" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E5" events="27" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemoglobin urine positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="7" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Kidney pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Protein urine positive</sub_title>
                <counts group_id="E1" events="111" subjects_affected="14" subjects_at_risk="26"/>
                <counts group_id="E2" events="124" subjects_affected="30" subjects_at_risk="58"/>
                <counts group_id="E3" events="67" subjects_affected="17" subjects_at_risk="27"/>
                <counts group_id="E4" events="187" subjects_affected="35" subjects_at_risk="57"/>
                <counts group_id="E5" events="341" subjects_affected="37" subjects_at_risk="55"/>
                <counts group_id="E6" events="70" subjects_affected="12" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="12" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="5" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urogenital disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="10" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Perineal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vaginal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vaginal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vaginal mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vaginal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="21" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="31" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E2" events="25" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="14" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E5" events="19" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="18" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="13" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E5" events="12" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E6" events="26" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" events="76" subjects_affected="19" subjects_at_risk="58"/>
                <counts group_id="E3" events="10" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E4" events="84" subjects_affected="22" subjects_at_risk="57"/>
                <counts group_id="E5" events="83" subjects_affected="21" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hiccough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="19" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E5" events="28" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="16" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="11" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E5" events="14" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="50" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="50" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Respiratory tract hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tracheal mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="21" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="14" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="14" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="28" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E5" events="30" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="53" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="31" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E5" events="29" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hand-and-foot syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="15" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="7" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="23" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="46" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" events="42" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="22" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E5" events="89" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="84" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" events="38" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E3" events="13" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E4" events="22" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E5" events="39" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="90" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" events="86" subjects_affected="20" subjects_at_risk="58"/>
                <counts group_id="E3" events="15" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E4" events="86" subjects_affected="21" subjects_at_risk="57"/>
                <counts group_id="E5" events="123" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="26" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" events="42" subjects_affected="15" subjects_at_risk="58"/>
                <counts group_id="E3" events="27" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E4" events="70" subjects_affected="15" subjects_at_risk="57"/>
                <counts group_id="E5" events="122" subjects_affected="25" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Scalp pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="16" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="11" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E5" events="42" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="8" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" events="9" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="131" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E2" events="174" subjects_affected="34" subjects_at_risk="58"/>
                <counts group_id="E3" events="43" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E4" events="186" subjects_affected="39" subjects_at_risk="57"/>
                <counts group_id="E5" events="365" subjects_affected="35" subjects_at_risk="55"/>
                <counts group_id="E6" events="145" subjects_affected="21" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lymph leakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="31" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="13" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E5" events="14" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Henry Pitot, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>(507) 284-2511</phone>
      <email>pitot.henry@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

